away. 1, 7, 8 Further, SLNB use has been associated with patient-level factors including marital status and race, as well as health system factors such as insurance status and hospital type. 9, 10 We hypothesized that the distance a patient travels for care may also have an important impact on the likelihood of undergoing SLNB for thin melanoma.
While distance traveled has been studied in the context of surgical outcomes, its influence on clinical decision-making is not well defined. [11] [12] [13] [14] It is often thought that patients travel for care when "local" expertise is not available, particularly when their disease requires complex decision-making. Therefore, greater SLNB use may be seen among patients who travel farther for care due to the influence of referral patterns for complex decisionmaking. Further, strong patient preference may play a role, even when indications for a procedure are less clear. It was our objective to assess the effect of distance traveled for care on the likelihood of a patient undergoing the SLNB for thin melanoma.
2 | METHODS
| Data source
We used the Melanoma Participant User File (1998-2011) from the National Cancer DataBase (NCDB). The NCDB is cosponsored by the American College of Surgeons and the American Cancer Society and captures 70% of index cancer diagnoses within the United States. 15 Over 1500 Commission on Cancer (CoC) hospitals contribute data to the NCDB.
| Study population
We identified all patients with clinically node-negative thin melanoma (≤1 mm in depth). Since the presence of ulceration or a high mitotic index (≥1 mitosis/mm 2 ) possibly increases the likelihood of nodal metastasis and likely influences the decision to perform an SLNB, we excluded patients who were missing these important histological details ( Figure 1 ). Next, we excluded patients missing key demographic or socioeconomic details (education, income-level, insurance status, and urban/rural designation of home zip code). This resulted in a cohort with complete histological (ulceration and mitotic index), clinicopathological (age, sex, and Charlson-Deyo comorbidity-index), and demographic details (race, education, income-level, insurance status, and urban/rural designation of home zip code). We compared the characteristics of patients in the final cohort and the excluded patients to ensure that no systematic difference existed between the two groups.
| Primary exposure
Our primary exposure was the distance traveled for surgical care.
The NCDB has previously been used to evaluate travel distance. 12, 16, 17 Distance using the "great circle distance," which is the number of miles between the patient's zip code of residence and the treating facility's zip code, is used in this analysis. If a patient resided in the same zip code as the treating facility, their distance traveled is calculated as zero miles. We categorized the distance traveled as short (<12.5 miles), intermediate (12.5-49 .9 miles), and long (≥50 miles). These designations were chosen based on prior distance work, which has used 50 miles as a benchmark for long distance. 16, 18 F I G U R E (Table 1 ). Relative to patients who traveled a short distance, those who traveled a long distance were more likely to be from rural counties (8.8% vs 0.0%, P < 0.001) and areas with median household income below $30 000 (17.3% vs 5.0%,
Patients who traveled a long distance were also more likely to receive care at academic or research programs than those who traveled less than 12.5 miles (74.9% vs 43.8%, P < 0.001).
Overall, SLNB was performed in 32.8% of patients with thin melanoma, and a higher proportion of patients who traveled a long distance received a SLNB than those who traveled an intermediate or short distance (35.1% vs 34.5% vs 30.9%, P < 0.001, respectively).
The percentage of positive SLNB was 5.5% in the short travel distance group, 6.0% in the intermediate travel distance group, and 7.7% in the long travel distance group.
| Characteristics associated with SLNB
Ulceration was more common among patients who received a SLNB than those who did not receive a SLNB (11.4% vs 2.7%, P < 0.001, Table 2 ). Similarly, a higher proportion of patients who received a SLNB had a mitotic index ≥1/mm 2 (56.8% vs 18.9%, P < 0.001). Rates of SLNB were also higher in younger patients, with 40.2% of 18 to 35-year-olds, 37.9% of 36 to 55-year-olds, 32.4% of 56 to 75-year-olds, and 21.4% of patients older than 75 years of age receiving a SLNB. Furthermore, SLNB use in thin melanoma was more common in patients from areas of lower educational attainment and lower median household income.
| Travel distance as a predictor of SLNB receipt
In the crude logistic regression model, traveling farther for care of thin melanoma was associated with a step-wise increase in the likelihood of undergoing a SLNB (P-trend < 0.001). Specifically, A secondary analysis was performed in which we defined the SLNB as the examination of 1 to 5 regional lymph nodes, and this did not alter the findings. The farther patients traveled the more likely they were to receive an SLNB.
| Subgroup analysis
On subgroup analysis, we stratified by tumor categories of T1a and 
| DISCUSSION
Although the routine SLNB is not recommended for thin melanoma, we found that 32.8% of patients with thin melanoma underwent a SLNB, and that SLNB was more common among patients who traveled a longer distance for care. This finding persisted despite adjustment for high-risk pathological features, indicating that the distance a patient travels for care is independently associated with the likelihood that they underwent a SLNB.
Travel distance and its impact on patient care is often studied in the context of surgical outcomes ( traveling to high-volume centers for pancreatic resections was associated with lower perioperative complication and improved mortality. 13 Similarly, Xu et al noted that patients who traveled to high-volume centers for rectal cancer operations experienced better overall survival. 14 These results suggest that travel distance is an important factor in contemporary surgical practice.
Although the volume-outcome relationship may explain some of the findings reported by Lidsky and Xu, patients who are willing to travel for care may be inherently different healthcare consumers.
This latter concept is often labeled the "distance bias" and may represent a selection bias, since relatively healthier patients are more apt to travel. 19, 21 For example, among patients who participated in phase II oncologic clinical trials, those who traveled farther had improved survival, despite the fact that all patients received care at the same quaternary center. 20 The distance bias may also manifest in patient preferences. A study conducted by Finlayson et al demonstrated that many patients preferred to receive their surgical care locally, despite operative mortality being four-times higher than the mortality at a high-volume regional center. 22 An extension of the distance bias suggests that patients who travel may have stronger preferences for certain types of care. Indeed, in the late 1990s and early 2000s, patients interested in a SLNB might have traveled to specialty centers to receive the care they desired. It is possible that the patients in our study, who traveled farther may have had stronger preference for nodal assessment. However, it is important to note that 98% of the patients in this study received care in 2010 and 2011, and the SLNB had been widely adopted by then.
Finally, travel distance has also been studied as a proxy for access to care. Traveling for care may not be a choice if patients don't live close to a center which offers the needed services. This may be the case for rural patients, and in this study, we found that 8.8% of There are limitations to our study. First, we used retrospective data from the National Cancer DataBase, which is subject to all the inherent biases of such a cohort, including lack of granular data and inability to capture actual decision-making processes. 
